The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...

Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...

Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s and Medincell announced that the supplemental ...

Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...

The FDA is reviewing risperidone (Uzedy) extended-release injectable suspension for maintenance treatment of adults with ...

The company credited much of that growth to higher generic sales around the world plus the continued strength of branded drugs Austedo, Uzedy and Ajovy. As for 2025, Teva expects to generate sales ...

There was a lot to like in Teva's Q4 report, notably: AUSTEDO and UZEDY had strong years, growing at 34% and 18% to $1.6B and $117M respectively. It should be noted that comparisons to Q4 2023 ...

Huntington's treatment Austedo and its schizophrenia drug Uzedy. Teva forecast 2025 revenue of $16.8 billion to $17.4 billion and diluted EPS ex-one offs of $2.35-$2.65. Analysts expect revenue of ...

UZEDY had a very strong year ... it was good to see external endorsement of the improvement of Teva with all the credit ratings improving their outlook for the company. And it's good to see ...

UZEDY Revenue: $117 million ... 2025 Free Cash Flow Guidance: $1.6 billion to $1.9 billion. Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported a 9% increase in revenue for 2024, reaching ...

The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy ...

UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...